Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoFuse in Multi-Level Anterior Cervical Discectomy and Fusion
NCT01097486Phase 2Completed
- Sponsor
- Mesoblast Ltd
- Start
- Jun 2010
- Primary completion
- Jul 2013
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of rexlemestrocel-l in degenerative disc disease (DDD) (2 arms), sponsored by Mesoblast Ltd. Primary endpoint: Safety of NeoFuse at 2 years. Started Jun 2010; status: completed.
02
Drugs
rexlemestrocel-l
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT01097486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01097486.